Clinical research
The company disclosed that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I trial for non-Hodgkin lymphoma due to a safety concern.
ACE-083 was the company’s lead product candidate for its neuromuscular therapeutic program.
The trial was assessing if multiple myeloma drug Empliciti could move forward as a front-line treatment for the disease.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
The stated cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.
The company said its combination treatment of Imfinzi (durvalumab) plus tremelimumab, an anti-CTLA4 antibody and Imfinzi on its own, did not improve overall survival in patients with this advanced form of bladder cancer.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
“This dosing is a truly historic event—for science, for medicine, and most importantly for people living with this eye disease,” said Cynthia Collins, president and chief executive officer of Editas.
Life sciences companies from across the globe provide updates on their businesses and pipelines.
In addition, the company’s chief scientific officer, Seth Ettenberg, has resigned.
PRESS RELEASES